Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program

The Journal of Headache and Pain

Research Article

Sue Lipscombe¹  Fayyaz Ahmed²  Nicola Giffin³  Peter J Goadsby⁴  Mark Weatherall⁵  Evelyn Kinsella⁶  Ria Bhola⁶ 

[1] Brighton and Sussex University Hospitals, Royal Sussex County, Brighton, UK;Department of Neurology, Hull Royal Infirmary, Hull, UK;Department of Neurology, Royal United Hospital, Bath, UK;Headache Group, Basic & Clinical Neuroscience, King’s College London, London, UK;NIHR-Wellcome Trust Clinical Research Facility, King’s College Hospital, SE5 9PJ, London, UK;Princess Margaret Migraine Clinic, Charing Cross Hospital, London, UK;eNeura Therapeutics, Sunnyvale, CA, USA;

关键词: Migraine;    Transcranial Magnetic Stimulation;    Topiramate;    Chronic Migraine;    Migraine With Aura;   

DOI  :  10.1186/s10194-015-0535-3

 received in 2015-02-05, accepted in 2015-05-25,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundSingle pulse transcranial magnetic stimulation (sTMS) is a novel treatment for acute migraine. Previous randomised controlled data demonstrated that sTMS is effective and well tolerated in the treatment of migraine with aura. The aim of the programme reported here was to evaluate patient responses in the setting of routine clinical practice.MethodsMigraine patients with and without aura treating with sTMS had an initial review (n = 426) and training call, and then participated in telephone surveys at week six (n = 331) and week 12 during a 3-month treatment period (n = 190).ResultsOf patients surveyed with 3 month data (n = 190; episodic, n = 59; chronic, n = 131), 62 % reported pain relief, finding the device effective at reducing or alleviating migraine pain; in addition there was relief reported of associated features: nausea- 52 %; photophobia- 55 %; and phonophobia- 53 %. At 3 months there was a reduction in monthly headache days for episodic migraine, from 12 (median, 8–13 IQ range) to 9 (4–12) and for chronic migraine, a reduction from 24 (median, 16–30 IQ range) to 16 (10–30). There were no serious or unanticipated adverse events.ConclusionsTMS may be a valuable addition to options for the treatment of both episodic and chronic migraine.

【 授权许可】

Unknown   
© Bhola et al. 2015. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.